Holen Sie sich die Stockscreener-App
0.5599
0.79%
0.0044
Schlusskurs vom Vortag:
$0.5555
Offen:
$0.5733
24-Stunden-Volumen:
49,119
Relative Volume:
0.08
Marktkapitalisierung:
$6.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.73M
KGV:
-0.0367
EPS:
-15.2598
Netto-Cashflow:
$-14.29M
1W Leistung:
-2.80%
1M Leistung:
-11.98%
6M Leistung:
-74.55%
1J Leistung:
-96.15%
1-Tages-Spanne:
$0.542
$0.5733
1-Wochen-Bereich:
$0.53
$0.7092
52-Wochen-Spanne:
$0.4229
$55.00
Genprex Inc Stock (GNPX) Company Profile
Firmenname
Genprex Inc
Sektor
Branche
Telefon
512-537-7997
Adresse
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.5599 | 6.12M | 0 | -16.73M | -14.29M | -15.26 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-26 | Eingeleitet | National Securities | Buy |
| 2019-04-29 | Eingeleitet | Noble Capital Markets | Outperform |
Genprex Inc Aktie (GNPX) Neueste Nachrichten
Genprex (GNPX) Hovers Near Support After Modest Gain, Consolidation Pattern EmergesGamma Squeeze - dars.gov.et
GNPX Q1 2026 Earnings: Clinical-Stage Biotech Reports Net Loss Per Share of $0.64 Amid Ongoing DevelopmentMargin Guidance - dars.gov.et
GNPX Q1 2026 Earnings: Net Loss of $0.64 Per Share as Stock Climbs 5.03%Forward Guidance Trends - dars.gov.et
Genprex | 8-K: Current report - Moomoo
$Genprex (GNPX.US)$ - Moomoo
GNPX Should I Buy - Intellectia AI
Enterprise value to EBIT forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Price to sales forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Price to earnings forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Price to book forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Enterprise value to revenue forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Genprex Inc Actuals & Estimates (NASDAQ:GNPX) - TradingView
Genprex’s Reqorsa combo secures Canadian patent for lung cancer - Yahoo Finance
GNPX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Genprex receives Canadian patent allowance for cancer therapy combination - Investing.com UK
Genprex, Inc. Files SEC Form 8-K: Company Details, Nasdaq Listing, and Key Corporate Information (June 22, 2026) - Minichart
Genprex (GNPX) Secures New Patent for Reqorsa Gene Therapy - GuruFocus
Form 8K Genprex Inc For: 22 June - Investing.com UK
Genprex Secures Canadian Patent for Reqorsa Lung Cancer Therapy - TipRanks
Form 8K Genprex Inc For: 22 June By Investing.com - Investing.com South Africa
Genprex receives Canadian patent allowance for cancer therapy combination By Investing.com - Investing.com South Africa
Genprex (NASDAQ: GNPX) secures Canadian patent for REQORSA lung cancer combinations - Stock Titan
Genprex Receives Notice of Allowance from the Canadian Intellectual Property Office for Patent Covering Reqorsa Gene Therapy Combination with PD-1 or PD-L1 Antibodies to Treat Cancer - marketscreener.com
Genprex Shareholders Approve Expanded Equity Plan, Reverse Split - The Globe and Mail
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Genprex (NASDAQ: GNPX) OKs equity plan and reverse split range - Stock Titan
Genprex Inc (GNPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Genprex Inc (GNPX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genprex Inc (GNPX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Genprex Inc (GNPX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Genprex Inc (GNPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genprex Inc (GNPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Genprex Inc (GNPX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Genprex Inc (GNPX) Institutional Confidence - TradingKey
Genprex Inc (GNPX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Genprex to Participate at BIO International Convention 2026 - Yahoo Finance
Genprex Faces Nasdaq Delisting Notice, Plans Compliance Steps - TipRanks
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GNPX Q1 2026 Earnings: Continued Losses as Clinical-Stage Biotech Focuses on Pipeline ProgressEarnings Miss Streak - newsline.com
Genprex, Inc. Files Form 8-K With Nasdaq Listing and Company Information – June 2026 - Minichart
Genprex faces potential delisting from Nasdaq after bid price rule violation - Investing.com UK
Genprex faces potential delisting from Nasdaq after bid price rule violation By Investing.com - Investing.com South Africa
Genprex Received Notice of Delisting - TradingView
Genprex (NASDAQ: GNPX) confronts Nasdaq delisting risk after sub-$1 bid price - Stock Titan
Genprex Inc. (GNPX) Edges Higher Amid Low-Volume Consolidation Near Key Support LevelsMid Cap Momentum - newsline.com
Genprex Inc. (GNPX) Edges Higher on Modest Volume, Faces Key Resistance at $0.68MA Cross Alert - newsline.com
Genprex Q1 2026 Earnings: Net Loss of $0.64 Per Share as Clinical-Stage Operations ContinueEarnings Surprise Report - newsline.com
Genprex (GNPX) files shelf registration to sell up to $250M in securities - Stock Titan
Genprex Files $250M Mixed Securities Shelf - Intellectia AI
GNPX Technical Analysis | Trend, Signals & Chart Patterns | GENPREX INC (NASDAQ:GNPX) - ChartMill
GNPX Q1 2026 Earnings: Net Loss Widens as Clinical-Stage Biotech Advances PipelineDownward Estimate Revision - dars.gov.et
Finanzdaten der Genprex Inc-Aktie (GNPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):